B ALL
Clinical trials for B ALL explained in plain language.
Never miss a new study
Get alerted when new B ALL trials appear
Sign up with your email to follow new studies for B ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedThis study tested a new treatment for children and young adults (ages 1-39) with B-cell leukemia or lymphoma that did not respond to standard therapy. Researchers took the patients' own white blood cells, modified them in a lab to target the CD22 protein on cancer cells, and infu…
Matched conditions: B ALL
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:02 UTC
-
New CAR-T therapy shows promise in tough leukemia cases
Disease control CompletedThis early-phase study tested a new immune cell therapy called ThisCART19A in 10 adults with a hard-to-treat type of leukemia (B-ALL) that had come back or stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see how well the th…
Matched conditions: B ALL
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Matched conditions: B ALL
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Partic…
Matched conditions: B ALL
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC